FDA
-
-
-
-
-
-
-
Evolus Announces Positive Data From Pivotal Trial for Evolysse™ Sculpt Injectable Hyaluronic Acid Gel Product at 2025 Cosmetic Bootcamp
-
-
-
-
-
-
-
Evolus Reports Record Fourth Quarter and Full-Year 2024 Financial Results; Reaffirms 2025 Guidance
-
-
-
-
-
-
-
Evolus Reports Second Quarter 2024 Results and Raises Full Year Revenue Guidance
-
-
-
-
-
-
-
Evolus Announces Publication of Safety and Duration Data from Phase 2 Study for “Extra-Strength” 40U Formulation of Jeuveau®
-
-
-
-
-
-
-
“Extra-Strength” 40U Formulation of Jeuveau® Demonstrates Effects Lasting 26 Weeks in Phase II Data Presented at 2023 ASDS Annual Meeting
-
-
-
-
-
-
-
"Extra-Strength" Formulation of Jeuveau® Demonstrates Effects Lasting 26 Weeks in Interim Phase II Data Results, Representing Prolonged 6-Month Performance
-
-
-
-
-
-
-
Peer-Reviewed Post Hoc Analysis Shows Jeuveau® is Highly Effective for Millennials by All Measures and at All Time Points Assessed
-
328,141 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

